|
TYW3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
6.5674999993881E-08 |
| Normal-vs-Stage3 |
4.17443857259059E-14 |
| Normal-vs-Stage4 |
1.99840144432528E-15 |
| Stage1-vs-Stage2 |
4.646000E-01 |
| Stage1-vs-Stage3 |
4.738400E-01 |
| Stage1-vs-Stage4 |
1.908330E-02 |
| Stage2-vs-Stage3 |
2.877800E-01 |
| Stage2-vs-Stage4 |
4.480000E-02 |
| Stage3-vs-Stage4 |
1.804970E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.01119999995625E-06 |
| Normal-vs-Asian |
8.88178419700125E-15 |
| Caucasian-vs-AfricanAmerican |
7.522800E-01 |
| Caucasian-vs-Asian |
6.964200E-02 |
| AfricanAmerican-vs-Asian |
2.325400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
3.477000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(41-60Yrs) |
1.48769885299771E-14 |
| Normal-vs-Age(61-80Yrs) |
1.69331215715829E-12 |
| Normal-vs-Age(81-100Yrs) |
7.84910000000139E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.626800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.345200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.258200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.616000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.539600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.510200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.612100E-02 |
| Classical-VS-Follicular |
3.755000E-01 |
| Classical-VS-Other |
3.782000E-01 |
| Classical-VS-Normal |
5.65925084572427E-12 |
| Tall-VS-Follicular |
1.470200E-02 |
| Tall-VS-Other |
8.976000E-01 |
| Tall-VS-Normal |
6.9066974361931E-13 |
| Follicular-VS-Other |
3.618600E-01 |
| Follicular-VS-Normal |
1.47130000405227E-08 |
| Other-VS-Normal |
3.244800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.27595720048157E-14 |
| Normal-vs-N1 |
1.11022302462516E-15 |
| N0-vs-N1 |
3.997900E-03 |
|
|
